A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

Conclusion.A 56‐day course of sirolimus was well tolerated in subjects with Cowden syndrome and was associated with some evidence of improvement in symptoms, skin and GI lesions, cerebellar function, and decreased mTOR signaling.

Source: The Oncologist - December 9, 2019 Category: Cancer & Oncology Authors: Takefumi Komiya, Gideon M. Blumenthal, Roopa DeChowdhury, Susan Fioravanti, Marc S. Ballas, John Morris, Thomas J. Hornyak, Stephen Wank, Stephen M. Hewitt, Betsy Morrow, Regan M. Memmott, Arun Rajan, Phillip A. Dennis Tags: Chinese Edition, Clinical Trial Results Source Type: research